<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585117</url>
  </required_header>
  <id_info>
    <org_study_id>HSC 2006-0282</org_study_id>
    <secondary_id>RO06309</secondary_id>
    <nct_id>NCT00585117</nct_id>
  </id_info>
  <brief_title>Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the
      basis for quantitative in vivo tumor imaging by Cu-61
      diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue hypoxia. We
      hypothesize that the hypoxia levels are predictive of the tumor response to therapy. Patients
      will have 2 CU-ATSM PET scans done and the goal is to show spatially stable tracer
      distributions that correlate with tumor hypoxia. This study will serve as a pilot study for a
      PO1 submission
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    change in imaging priorities
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To validate the CuATSM-PET imaging by correlation to the serum level of osteopontin, a marker of hypoxia</measure>
    <time_frame>end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To test reliability of the CuATSM uptake by quantifying the reproducibility of the pre-treatment CuATSM_PET scans</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the technical and logistic feasibility of CuATSM-PET scans in a population of cancer patients</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>CNS Brain Metastases</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>1 CNS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>imaging with CuATSM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Head and Neck</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imaging with CuATSM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Lung</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>imaging with CuATSM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Prostate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET imaging with CuATSM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5. Esophagus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PET imaging with CuATSM</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET-imaging with CuATSM</intervention_name>
    <description>imaging with CuATSM</description>
    <arm_group_label>1 CNS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET Imaging</intervention_name>
    <description>Imaging with CuATSM</description>
    <arm_group_label>1 CNS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET CuATSM</intervention_name>
    <description>Imaging with CuATSM</description>
    <arm_group_label>2. Head and Neck</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET imaging</intervention_name>
    <description>imaging with CuATSM</description>
    <arm_group_label>3. Lung</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET imaging with CuATSM</intervention_name>
    <description>Imaging with CuATSM</description>
    <arm_group_label>4. Prostate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET imaging with CuATSM</intervention_name>
    <description>Imaging with CuATSM</description>
    <arm_group_label>5. Esophagus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to tolerated a PET/CT scan

          -  Age 18 or older

          -  Patient being considered for XRT for treatment of their cancer

          -  Able to provide written informed consent

        Exclusion Criteria:

          -  severe claustrophobia or inability to tolerate the PET scan

          -  pregnant or breastfeeding women

          -  Patients that need supplemental oxygen

          -  Patients enrolled in experimental treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Jeraj, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

